Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INNOVATE: NovoTTF-100L(O) + Paclitaxel in Recurrent Ovarian Cancer
NCT02244502Phase 2Unknown
- Sponsor
- NovoCure
- Start
- Sep 2014
- Primary completion
- Dec 2016
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial in ovarian carcinoma, sponsored by NovoCure. Primary endpoints: Adverse Events Severity and Frequency at 1.5 years and Number of patients prematurely discontinuing TTFields due to Skin Toxicity at 1.5 years. Status: unknown.
02
Conditions
ovarian carcinoma
Beyond the preview
Go deeper on NCT02244502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02244502.